Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.

Publication Type:

Journal Article


Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Volume 20, Issue 4, p.619-27 (2011)


2011, Adult, Aged, Clinical Research Division, Genetic Variation, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Orchiectomy, Organic Anion Transporters, Organic Anion Transporters, Sodium-Independent, Polymorphism, Single Nucleotide, Prostatic Neoplasms, Public Health Sciences Division, Risk Factors, SEER Program, Treatment Outcome


Metastases from men with castration-resistant prostate cancer (CRPC) harbor increased tumoral androgens versus untreated prostate cancers. This may reflect steroid uptake by OATP (organic anion transporting polypeptide)/SLCO transporters. We evaluated SLCO gene expression in CRPC metastases and determined whether prostate cancer outcomes are associated with single nucleotide polymorphisms (SNP) in SLCO2B1 and SLCO1B3, transporters previously shown to mediate androgen uptake.